IRWD, RXRX, NVAX, VTRS and NTLA gear up for earnings as the Medical sector posts solid sales growth despite a slight profit ...

A drug selected for the latest round of Medicare drug price negotiations stands to get dropped because a lower-cost ...

Ray J sparked concern among fans during a Valentine’s Day concert in Louisiana after appearing on stage with what looked like ...

The singer previously stated he had months to live following a hospitalization, and was seen performing with blood streaming ...

Let's take a closer look at what awaits Bausch Health, Amicus Therapeutics, BioMarin Pharmaceutical, Insmed and Madrigal ...

Novartis posts positive phase III ALIGN data for Vanrafia in IgAN, showing slower kidney decline as it eyes full approval in 2026.

Breast cancer drug Kisqali outperformed its 2025 sales target by 9%, while a portfolio of recent launches that includes radioligand therapy Pluvicto, kidney disease drugs Fabhalta and Vanrafia, and ...

Novartis CEO Vas Narasimhan is doubling down on a growth forecast for 2026, even as the Swiss drugmaker’s fourth-quarter results start to show the impact of the “largest patent expiry” in its history.

By Ludwig Burger and Bhanvi Satija FRANKFURT, Feb 4 (Reuters) - Swiss drugmaker Novartis forecast a worse-than-expected decline in 2026 operating profit by a low single-digit percentage, held back by ...

The pharma major said it faces the largest drug-patent expiry headwind in its history this year.

While proven to help, primary care clinicians have been slow to use the drugs once considered only for patients with diabetes.